62 related articles for article (PubMed ID: 38383563)
21. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M; Zheng X; Niu M; Zhu S; Ge H; Wu K
Mol Cancer; 2022 Jan; 21(1):28. PubMed ID: 35062949
[TBL] [Abstract][Full Text] [Related]
22. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association.
Wu CC; Wang YA; Livingston JA; Zhang J; Futreal PA
Nat Commun; 2022 Jan; 13(1):42. PubMed ID: 35013211
[TBL] [Abstract][Full Text] [Related]
23. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.
Hammerl D; Martens JWM; Timmermans M; Smid M; Trapman-Jansen AM; Foekens R; Isaeva OI; Voorwerk L; Balcioglu HE; Wijers R; Nederlof I; Salgado R; Horlings H; Kok M; Debets R
Nat Commun; 2021 Sep; 12(1):5668. PubMed ID: 34580291
[TBL] [Abstract][Full Text] [Related]
24. CD8
Philip M; Schietinger A
Nat Rev Immunol; 2022 Apr; 22(4):209-223. PubMed ID: 34253904
[TBL] [Abstract][Full Text] [Related]
25. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.
Voabil P; de Bruijn M; Roelofsen LM; Hendriks SH; Brokamp S; van den Braber M; Broeks A; Sanders J; Herzig P; Zippelius A; Blank CU; Hartemink KJ; Monkhorst K; Haanen JBAG; Schumacher TN; Thommen DS
Nat Med; 2021 Jul; 27(7):1250-1261. PubMed ID: 34239134
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy.
DeVito NC; Sturdivant M; Thievanthiran B; Xiao C; Plebanek MP; Salama AKS; Beasley GM; Holtzhausen A; Novotny-Diermayr V; Strickler JH; Hanks BA
Cell Rep; 2021 May; 35(5):109071. PubMed ID: 33951424
[TBL] [Abstract][Full Text] [Related]
27. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer.
Chen J; Sun HW; Yang YY; Chen HT; Yu XJ; Wu WC; Xu YT; Jin LL; Wu XJ; Xu J; Zheng L
Signal Transduct Target Ther; 2021 Jan; 6(1):4. PubMed ID: 33414378
[TBL] [Abstract][Full Text] [Related]
28. Roles of IFN-γ in tumor progression and regression: a review.
Jorgovanovic D; Song M; Wang L; Zhang Y
Biomark Res; 2020; 8():49. PubMed ID: 33005420
[TBL] [Abstract][Full Text] [Related]
29. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Lei Q; Wang D; Sun K; Wang L; Zhang Y
Front Cell Dev Biol; 2020; 8():672. PubMed ID: 32793604
[TBL] [Abstract][Full Text] [Related]
30. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
31. Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.
Powley IR; Patel M; Miles G; Pringle H; Howells L; Thomas A; Kettleborough C; Bryans J; Hammonds T; MacFarlane M; Pritchard C
Br J Cancer; 2020 Mar; 122(6):735-744. PubMed ID: 31894140
[TBL] [Abstract][Full Text] [Related]
32. Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer.
Unterleuthner D; Neuhold P; Schwarz K; Janker L; Neuditschko B; Nivarthi H; Crncec I; Kramer N; Unger C; Hengstschläger M; Eferl R; Moriggl R; Sommergruber W; Gerner C; Dolznig H
Angiogenesis; 2020 May; 23(2):159-177. PubMed ID: 31667643
[TBL] [Abstract][Full Text] [Related]
33. Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?
Callahan MK; Wolchok JD
Cancer Cell; 2019 Sep; 36(3):215-217. PubMed ID: 31526757
[TBL] [Abstract][Full Text] [Related]
34. The Tumor Microenvironment Innately Modulates Cancer Progression.
Hinshaw DC; Shevde LA
Cancer Res; 2019 Sep; 79(18):4557-4566. PubMed ID: 31350295
[TBL] [Abstract][Full Text] [Related]
35. Wnt Signaling: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Javed Z; Muhammad Farooq H; Ullah M; Zaheer Iqbal M; Raza Q; Sadia H; Pezzani R; Salehi B; Sharifi-Rad J; Cho WC
Asian Pac J Cancer Prev; 2019 Apr; 20(4):995-1003. PubMed ID: 31030466
[TBL] [Abstract][Full Text] [Related]
36. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
37. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
Zhao F; Evans K; Xiao C; DeVito N; Theivanthiran B; Holtzhausen A; Siska PJ; Blobe GC; Hanks BA
Cancer Immunol Res; 2018 Dec; 6(12):1459-1471. PubMed ID: 30209062
[TBL] [Abstract][Full Text] [Related]
38. Notch Signaling in the Tumor Microenvironment.
Meurette O; Mehlen P
Cancer Cell; 2018 Oct; 34(4):536-548. PubMed ID: 30146333
[TBL] [Abstract][Full Text] [Related]
39. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ
Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310
[TBL] [Abstract][Full Text] [Related]
40. QuPath: Open source software for digital pathology image analysis.
Bankhead P; Loughrey MB; Fernández JA; Dombrowski Y; McArt DG; Dunne PD; McQuaid S; Gray RT; Murray LJ; Coleman HG; James JA; Salto-Tellez M; Hamilton PW
Sci Rep; 2017 Dec; 7(1):16878. PubMed ID: 29203879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
